Gene editing had a banner year in 2023
This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every
Read MoreThis article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every
Read MoreVertex Pharmaceuticals has agreed to buy rights to use a dominant CRISPR patent owned by the Broad Institute of Harvard
Read MoreThe world’s first commercial gene-editing treatment is set to start changing the lives of people with sickle-cell disease. It’s called Casgevy,
Read MoreThat’s a real nice CRISPR cure you have there. It would be a pity if anything happened to it. Okay.
Read MoreThis tax software company can now focus on expanding margins thanks to the completion of an investment cycle, the firm
Read MoreTwenty-five years ago, in 1998, researchers in Wisconsin isolated powerful stem cells from human embryos. It was a fundamental breakthrough
Read MoreAs tech firms shift focus from growth to profitability, Goldman names 5 stocks to buy. Source link
Read MoreCNBC Pro subscribers can see the stocks that passed the firm's screen. Source link
Read MoreCNBC Pro takes a look at the favorite software stocks of Wall Street banks, including one "prime bounce-back candidate." Source
Read More